TuHURA Biosciences has secured a $50 million credit facility to fund its lead cancer therapy program through Phase 3 results and extend its cash runway into 2028.
The financing, announced April 22, is structured as a loan agreement with an affiliate of the company’s largest shareholder, K&V Investment One LLC. TuHURA can draw funds monthly, as needed, to support operations and advance its clinical pipeline.
The facility carries a 12% annual interest rate on funds drawn, with interest paid monthly and the full principal due at maturity on April 21, 2031. The loan is secured by the company’s assets and includes a royalty provision granting the lender a low- to mid-single-digit percentage of future sales tied to IFx-2.0, the company’s lead product candidate.
Read the latest Tampa news and updates
The financing provides capital without issuing equity as the company advances late-stage development, allowing TuHURA to fund operations while preserving flexibility to pursue partnerships or additional capital.
The funding is expected to carry IFx-2.0 through anticipated Phase 3 testing. The therapy is being studied in combination with Keytruda for advanced or metastatic Merkel cell carcinoma. TuHURA is also advancing TBS-2025, a monoclonal antibody acquired through its 2025 merger with Kineta, as well as earlier-stage programs.
The financing supports TuHURA’s effort to advance therapies targeting resistance to cancer immunotherapy as it moves toward key clinical milestones.
Read More Tampa Bay Business News
Explore the latest Tampa Bay business news, real estate deals, development projects, executive moves and company updates shaping the region.